Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APM Aptorum Group	$1.32 -2.9%	$1.27	$0.46 ▼ $7.49	$7.06M	-0.1	1.50 million shs	82,210 shs
KZR Kezar Life Sciences	$3.88 +0.5%	$4.34	$3.62 ▼ $9.18	$28.41M	0.65	39,024 shs	80,738 shs
MAAQ Mana Capital Acquisition	$3.72 +2.5%	$3.96	$5.35 ▼ $10.25	$48.67M	N/A	33,075 shs	58,950 shs
PHGE BiomX	$0.53 -27.7%	$0.45	$0.34 ▼ $2.40	$14.81M	1.42	347,190 shs	53,300 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APM Aptorum Group	-2.16%	-4.23%	-15.53%	+50.11%	-57.50%
KZR Kezar Life Sciences	-2.77%	-1.78%	-11.26%	-6.08%	-37.07%
MAAQ Mana Capital Acquisition	0.00%	+5.22%	-15.58%	-17.87%	+758.16%
PHGE BiomX	-5.95%	-2.43%	+31.16%	-3.51%	-68.72%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
APM Aptorum Group	0.6902 of 5 stars	0.0	2.0	0.0	0.0	2.5	1.7	0.6
KZR Kezar Life Sciences	3.6742 of 5 stars	3.2	0.0	0.0	4.6	2.0	2.5	0.6
MAAQ Mana Capital Acquisition	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PHGE BiomX	2.4212 of 5 stars	3.5	0.0	0.0	0.0	2.1	0.8	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APM Aptorum Group	0.00	N/A	N/A	N/A
KZR Kezar Life Sciences	2.33	Hold	$9.00	131.96% Upside
MAAQ Mana Capital Acquisition	0.00	N/A	N/A	N/A
PHGE BiomX	3.00	Buy	$21.00	3,832.58% Upside

Current Analyst Ratings Breakdown

Latest APM, PHGE, KZR, and MAAQ Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
7/16/2025	KZR Kezar Life Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral

(Data available from 8/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APM Aptorum Group	$430K	16.42	N/A	N/A	$2.20 per share	0.60
KZR Kezar Life Sciences	N/A	N/A	N/A	N/A	$16.02 per share	N/A
MAAQ Mana Capital Acquisition	N/A	N/A	N/A	N/A	N/A	N/A
PHGE BiomX	N/A	N/A	N/A	N/A	$0.70 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APM Aptorum Group	-$4.27M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
KZR Kezar Life Sciences	-$83.74M	-$9.69	N/A	N/A	N/A	N/A	-63.51%	-52.13%	N/A
MAAQ Mana Capital Acquisition	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
PHGE BiomX	-$28.32M	-$1.36	N/A	N/A	N/A	N/A	-127.82%	-56.50%	N/A

Latest APM, PHGE, KZR, and MAAQ Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/13/2025	Q2 2025	KZR Kezar Life Sciences	-$2.15	-$1.87	+$0.28	-$1.87	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
APM Aptorum Group	N/A	N/A	N/A	N/A	N/A
KZR Kezar Life Sciences	N/A	N/A	N/A	N/A	N/A
MAAQ Mana Capital Acquisition	N/A	N/A	N/A	N/A	N/A
PHGE BiomX	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APM Aptorum Group	N/A	0.22	0.22
KZR Kezar Life Sciences	0.03	7.29	7.29
MAAQ Mana Capital Acquisition	N/A	N/A	N/A
PHGE BiomX	0.51	2.84	2.84

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
APM Aptorum Group	3.80%
KZR Kezar Life Sciences	67.90%
MAAQ Mana Capital Acquisition	68.44%
PHGE BiomX	40.57%

Insider Ownership

Company	Insider Ownership
APM Aptorum Group	63.99%
KZR Kezar Life Sciences	9.30%
MAAQ Mana Capital Acquisition	N/A
PHGE BiomX	1.17%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
APM Aptorum Group	30	5.35 million	1.93 million	Not Optionable
KZR Kezar Life Sciences	60	7.32 million	6.64 million	Not Optionable
MAAQ Mana Capital Acquisition	1	8.13 million	N/A	Not Optionable
PHGE BiomX	120	26.53 million	44.04 million	Not Optionable

APM, PHGE, KZR, and MAAQ Headlines

Recent News About These Companies

BiomX Provides Update on BX004 Phase 2b Trial for the Treatment of Patients with Cystic Fibrosis

August 19 at 8:19 AM | globenewswire.com

BiomX Posts Q2 Loss With 14% Cost Drop

August 14, 2025 | aol.comA

BiomX Inc. (PHGE) Q2 2025 Earnings Call Transcript

August 13, 2025 | seekingalpha.com

BiomX Reports Second Quarter 2025 Financial Results and Provides Program Updates

August 13, 2025 | globenewswire.com

What to Expect from BiomX's Earnings

August 12, 2025 | benzinga.com

BiomX to Report Second Quarter 2025 Financial Results and Program Updates on August 13, 2025

August 6, 2025 | globenewswire.com

BiomX stock soars after initiating Phase 2b trial for cystic fibrosis therapy

July 14, 2025 | investing.com

BiomX Shares Surge 60% Following Start of Phase 2b Trial for Cystic Fibrosis Treatment

July 14, 2025 | msn.com

PHGE | BiomX Inc. Stock Overview (U.S.: NYSE American) | Barron's

July 14, 2025 | barrons.com

BiomX Announces Successful Initiation of Phase 2b Trial with First Patient Dosed in BX004 Program in Patients with Cystic Fibrosis

July 14, 2025 | globenewswire.com

BiomX Announces Publication in Nature Communications of Phage Cocktail BX004 Phase 1b/2a Part 1 Data Demonstrating Strong Activity in Cystic Fibrosis

July 8, 2025 | globenewswire.com

BiomX Inc. to Present Positive Phase 2 Results for BX211 at Biomed Israel 2025 Conference

May 21, 2025 | nasdaq.com

BiomX CEO Jonathan Solomon to Present at Biomed Israel 2025 Conference

May 19, 2025 | globenewswire.com

BiomX Inc. (AMEX:PHGE) Q1 2025 Earnings Call Transcript

May 17, 2025 | msn.com

BiomX Inc. (PHGE) Q1 2025 Earnings Conference Call Transcript

May 15, 2025 | seekingalpha.com

BiomX Reports First Quarter 2025 Financial Results and Provides Business and Program Updates

May 15, 2025 | globenewswire.com

BiomX to Host First Quarter 2025 Financial Results Conference Call and Webcast on May 15, 2025

May 8, 2025 | globenewswire.com

BiomX (PHGE) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

April 18, 2025 | zacks.com

BiomX announces going concern qualification from independent audit

April 1, 2025 | markets.businessinsider.com

BiomX target adjusted to $21 from $2 at H.C. Wainwright

April 1, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

APM, PHGE, KZR, and MAAQ Company Descriptions

Aptorum Group NASDAQ:APM

$1.32 -0.04 (-2.94%)

Closing price 04:00 PM Eastern

Extended Trading

$1.30 -0.03 (-1.89%)

As of 06:53 PM Eastern

Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A. The company is also developing ALS-2/3 for the treatment of gram+ve bacterial infections; RPIDD, a pathogen molecular diagnostic; NativusWell DOI (NLS-2), a dietary supplement; NLS-1 for the treatment of endometriosis; DLS-1+2 to treat NSCLC with mutation; DLS-3, an autoimmune small molecule; and CLS-1 for the treatment of obesity. Its pipeline products enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platforms for treatment of metabolic diseases. The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. In addition, it operates a medical clinic. The company was formerly known as APTUS Holdings Limited and changed its name to Aptorum Group Limited in October 2017. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom. Aptorum Group Limited is a subsidiary of Jurchen Investment Corporation.

Kezar Life Sciences NASDAQ:KZR

$3.88 +0.02 (+0.52%)

Closing price 04:00 PM Eastern

Extended Trading

$3.88 0.00 (-0.13%)

As of 04:58 PM Eastern

Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Mana Capital Acquisition NASDAQ:MAAQ

$3.72 +0.09 (+2.48%)

As of 08/18/2025

Mana Capital Acquisition Corp. focuses on engaging in a merger, stock exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combination with one or more businesses or entities. It intends to focus on businesses operating in the healthcare, technology, green economy, and consumer products sectors in North America, Europe, and Asia. The company was incorporated in 2021 and is based in Dover, Delaware.

BiomX NYSEMKT:PHGE

$0.53 -0.21 (-27.74%)

Closing price 03:58 PM Eastern

Extended Trading

$0.51 -0.02 (-3.93%)

As of 07:06 PM Eastern

BiomX Inc., a clinical-stage biopharmaceutical company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic disease. It is developing BX211, a phage therapy, which is in phase 2 clinical study for the treatment of diabetic foot osteomyelitis. The company's product pipeline also includes BX004, a phage therapy for cystic fibrosis patients with chronic pulmonary infections caused by Pseudomonas aeruginosa that is in Phase 1b/2a clinical trials. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time